LIMItIng AAA With meTformin (LIMIT) Trial
Stanford University
Summary
In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
Eligibility
- Age range
- 50–95 years
- Sex
- All
- Healthy volunteers
- No
7.2 Inclusion Criteria 1. Provision of signed and dated informed consent; 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 50 to 95 years inclusive; 4. Have a maximal orthogonal infrarenal aortic diameter between 35 and \< 50 mm for males and between 30 and \< 45 mm for females as measured by CTA; 5. Eligible participants must have an estimated glomerular filtration rate (eGFR) of ≥ 30 ml/min/1.73 m2 at the initiation of trial participation, and must remain ≥ 30 ml/min/1.73 m2 throughout the term of the study to c…
Interventions
- DrugMetformin
Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
- OtherPlacebo
One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
Location
- Stanford Hospital and ClinicsStanford, California